Singapore cell therapy hub to deliver products for world

SCG Cell Therapy plans to establish Singapore as its international hub for cell therapy research, manufacturing and clinical development to deliver products across Asia Pacific, the USA, Europe and the world.

In line with this, the biotech company has signed an agreement with the Cell Therapy Facility of Singapore Health Sciences Authority (HSA-CTF) for the evaluation and validation of SCG’s proprietary cell therapy manufacturing process to develop a new treatment option for patients with hepatitis B virus-related hepatocellular carcinoma.

"Singapore is an attractive location to set up an international hub"The process validation will be performed in the Good Manufacturing Practice (GMP)-certified facility at HSA-CTF. SCG Cell Therapy will use the validation result to support global Investigational New Drug Application of SCG101 – autologous T-cell receptor T cell therapy.